The Latest Breaking News from FDA

Paxlovid good at stopping hospitalisation for high-risk groups, despite occasional rebound

Biosimulation leader Certara recently inked a deal with a leading cancer research institution. Does it matter to investors?

Here's a roundup of top developments in the biotech space over the last 24 hours:

CNBC

Gainers MAIA Biotechnology, Inc. (NASDAQ: MAIA) rose 37.9% to $8.00 in pre-market trading after jumping 30% on Friday. The company agreed to initially offer 2.00 million shares to the public at a $5.00 per share.

Avoiding unseen food hazards is the reason people often check the dates on food packaging.

The FDA has effectively thrown up its hands over its most important food-related role.

Though doctors and advocates have helped speed up access to the antiviral pills – of which the U.S. has enough to treat 1.7 million people – health providers are few and forms are still required.

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…